serial imaging of the novel radiotracer [^18f] fluorthanatrace ([^18f] ftt) by pet/ctf

Conditions: Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm

Summary: this phase i trial studies how well fluorine f 18 fluorthanatrace positron emission tomography (pet)/computed tomography (ct) works in patients with solid tumors. fluorine f 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. pet/ct uses a scanner to make detailed, computerized pictures of areas inside the body. pet/ct with fluorine f 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.

primary objectives: - evaluate fluorine f 18 fluorthanatrace (\[18f\]fluorthanatrace) positron emission tomography/computed tomography (pet/ct) as an imaging biomarker of poly \[adp-ribose\] polymerase (parp)-1 activity in 3 cohorts of cancer patients: 1) ovarian, fallopian tube, primary peritoneal 2) breast cancer, and 3) non-ovarian, non-breast solid tumor. secondary objectives: * evaluate the safety of \[18f\]fluorthanatrace. * correlate \[18f\]fluorthanatrace uptake measures with brca mutation status. * correlate \[18f\]fluorthanatrace uptake measures with poly \[adp-ribose\] polymerase (parp-1) activity in tumor tissue samples in patients who undergo biopsies. * evaluate change in \[18f\]fluorthanatrace uptake measures after therapy initiation with repeat imaging before and after treatment initiation. * to confirm the variability of imaging findings from repeated \[18f\]ftt pet/ct over 1 week before treatment initiation * determine the change in \[18f\]fluorthanatrace uptake before treatment initiation and at time of clinical progression * correlate \[18f\]fluorthanatrace uptake at time of clinical progression measures with genetic reversion mutation status outline: patients receive fluorodeoxyglucose (fdg) intravenously (iv) and undergo fdg pet/ct scan over 20-30 minutes if they have not already had one per standard of care. at least 20-24 hours later, patients receive fluorine f 18 fluorthanatrace iv and undergo fluorine f 18 fluorthanatrace (\[18f\]ftt) pet/ct over 1 hour. after completion of study treatment, patients are followed up at 24 hours.

Eligibility criteria:
inclusion criteria: * history of known or suspected solid tumor. * at least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \[ct\], magnetic resonance imaging \[mri\], ultrasound, fludeoxyglucose \[fdg\] pet/ct). exclusion criteria: * females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \< 2 weeks prior to screening as standard of care. * inability to tolerate imaging procedures in the opinion of an investigator or treating physician. * any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.